Journal
EXPERT OPINION ON DRUG SAFETY
Volume 17, Issue 2, Pages 139-147Publisher
TAYLOR & FRANCIS LTD
DOI: 10.1080/14740338.2018.1400530
Keywords
Tumor necrosis factor alpha inhibitors; angiotensinreceptor blockers; phosphodiesterase type 5 inhibitors; HMG-CoA-reductase inhibitors; statins; basal cell carcinoma; squamous cell carcinoma; non-melanoma skin cancer; skin cancer; melanoma
Categories
Ask authors/readers for more resources
Introduction: Skin cancers, including both malignant melanoma (MM) and nonmelanoma skin cancer (NMSC), are the most commonly diagnosed cancers in the US. The incidence of both MM and NMSC continues to rise. Areas covered: Current evidence for an association between four of the most commonly prescribed classes of drugs in the U.S. and risk for MM and NMSC is reported. Medline was searched (January 2000 to May 2017) for each drug in the classes and for 'basal cell carcinoma', 'squamous cell carcinoma', 'non-melanoma skin cancer', 'skin cancer' and 'melanoma'. Skin cancer risk information was reported for: tumor necrosis factor alpha inhibitors (TNF-aIs), angiotensin-receptor blockers (ARBs), phosphodiesterase type 5 inhibitors (PDE5Is) and 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA)-reductase inhibitors (statins). Expert opinion: Since skin cancer risk is associated with all four classes of these commonly prescribed drugs that represent nearly 20% of the Top 100 drugs in the U.S., these important findings warrant enhanced education, especially for prescribers and those patients at high risk for skin cancer.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available